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Abstract
Introduction: The DAWN trial demonstrated the effectiveness of late endovascular treatment in acute ischemic stroke
patients selected on the basis of a clinical-core mismatch. We explored in a real-world sample of endovascular treatment
patients if a clinical-ASPECTS (Alberta Stroke Program Early CT Score) mismatch was associated with an outcome
benefit after late endovascular treatment.
Methods: We retrospectively analyzed all consecutive acute ischemic stroke patients admitted 6–24 h after last proof of
good health in two stroke centers, with initial National Institutes of Health Stroke Scale (NIHSS) 10 and an internal
carotid artery or M1 occlusion. We defined clinical-ASPECTS mismatch as NIHSS 10 and ASPECTS 7, or NIHSS 20
and ASPECTS 5. We assessed the interaction between the presence of the clinical-ASPECTS mismatch and late
endovascular treatment using ordinal shift analysis of the three-month modified Rankin Scale and adjusting for multiple
confounders.
Results: The included 337 patients had a median age of 73 years (IQR¼ 61–82), admission NIHSS of 18 (15–22), and
baseline ASPECTS of 7 (5–9). Out of 196 (58.2%) patients showing clinical-ASPECTS mismatch, 146 (74.5%) underwent
late endovascular treatment. Among 141 (41.8%) mismatch negative patients, late endovascular treatment was per-
formed in 72 (51.1%) patients. In the adjusted analysis, late endovascular treatment was significantly associated with a
better outcome in the presence of clinical-ASPECTS mismatch (adjusted odd ratio, aOR¼ 2.83; 95% confidence interval,
CI: 1.48–5.58) but not in its absence (aOR¼ 1.32; 95%CI: 0.61–2.84). The p-value for the interaction term between
clinical-ASPECTS mismatch and late endovascular treatment was 0.073.
Conclusions: In our retrospective two-site analysis, late endovascular treatment seemed effective in the presence of a
clinical-ASPECTS mismatch, but not in its absence. If confirmed in randomized trials, this finding could support the use of
an ASPECTS-based selection for late endovascular treatment decisions, obviating the need for advanced imaging.
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Recent randomized clinical trials have provided class I
evidence for the efficacy of endovascular treatment
(EVT) in acute ischemic stroke (AIS) patients from
proximal anterior circulation large vessel occlusion
(LVO) in the late-time window, if properly selected
based on their neuroimaging profile.1–3 However, we
previously demonstrated that the proportion of late-
admitted AIS eligible for EVT according to strict trial
criteria was low in the real-life scenario.4
Enlarging the selection criteria for late EVT could
allow a larger population of AIS patients to benefit
from the revascularization procedures. Notably, the
use of a simpler neuroimaging protocol could help
with the decision to proceed with mechanical thromb-
ectomy in case of absent, failed or contraindicated
advanced imaging, or in situations of discordant ima-
ging profile.5
The Alberta Stroke Program Early CT Score
(ASPECTS) is an easily applicable tool to estimate
the amount of irreversibly damaged brain tissue in the
middle cerebral artery (MCA) territory strokes.6
Originally designed for non-contrast CT scan
(NCCT), it has been also applied to diffusion-weighted
imaging (DWI) sequences, after one-point adjustment.7
However, the role of ASPECTS in selecting patients
who are most likely to benefit from EVT is not clearly
established in the late time window.8,9 Also, to the best
of our knowledge, its use in association of clinical
stroke severity as a surrogate of the core-penumbra
mismatch1 has not been evaluated.
The main aim of our study was to analyze the clin-
ical outcome of late-arriving AIS patients with prox-
imal anterior circulation LVO depending on the
presence of a clinical-ASPECTS mismatch and of treat-
ment with mechanical thrombectomy in two compre-
hensive stroke centers.
Methods
Study design and study population
We performed a retrospective analysis of all consecu-
tive AIS patients who received mechanical thrombec-
tomy in the late time window in the comprehensive
stroke centers of Lausanne and Berne University
Hospitals from January 2010 to December 2018. Data
were extracted from the prospectively constructed
stroke registry of each institution, whose details have
been previously published.10,11
For the current analysis, we adopted the following
inclusion criteria: anterior circulation stroke with prox-
imal LVO (i.e. occlusion of intracranial internal carotid
artery (ICA), and/or M1 segment of the MCA);
National Institutes of Health Stroke Scale (NIHSS)
on admission 10; mechanical thrombectomy started
between 6 and 24 h since last proof of good
health (LPGH); and availability of three-month func-
tional status, assessed with the modified Rankin
scale (mRS).
For the current analysis, we defined a ‘‘clinical-
ASPECTS mismatch’’ as the presence of NIHSS 10
combined with ASPECTS 7 or NIHSS 20 asso-
ciated with ASPECTS 5. The ASPECTS was visually
scored on the first unenhanced neuroimaging modality
(NCCT or diffusion-weighted magnetic resonance ima-
ging, DWI) obtained on admission. The clinical-
ASPECTS definition was inspired by the clinical-core
mismatch used in the DAWN trial,1 and based on the
ASPECTS/CTP-core correlation that we previously
investigated.12 In order to adjust for the higher sensi-
tivity of DWI, one point was added before analysis for
DWI-ASPECTS.7 Unlike the DAWN trial, we did not
apply any age or pre-stroke functional disability cut-
off, in order to present a closer picture to the real-life
scenario. We therefore identified a group of
treated patients presenting the clinical-ASPECTS mis-
match (‘‘mismatch positive-EVT’’), and a group of
treated patients with ASPECTS <5 or not showing
the clinical-ASPECTS mismatch (‘‘mismatch negative-
EVT’’).
As control group, we selected all consecutive AIS
admitted to the Lausanne University Hospital in the
late time window, and not receiving EVT (intravenous
thrombolysis, IVT, allowed). The inclusion period for
this group was extended from 2005 to 2018 to ensure a
satisfactory sample size. The same clinical (i.e. NIHSS
10) and radiological (ICA or M1 occlusion) inclusion
criteria were applied. Similarly, we identified two
groups of non-treated patients: the ‘‘mismatch posi-
tive-no EVT’’ group, corresponding to non-treated
patients showing the clinical-ASPECTS mismatch,
and ‘‘mismatch negative -no EVT’’ group, i.e. non trea-
ted patients with ASPECTS <5 or without the clinical-
ASPECTS mismatch.
Details on the neuroimaging protocol of each parti-
cipating center, ASPECTS scoring and adopted EVT
guidelines have been published before,12,13 and add-
itional information are provided in the Supplementary
Material.
The primary outcome of the study was the shift
towards better functional outcome in the three-month
mRS in the ‘‘mismatch positive-EVT’’ group compared
to the ‘‘mismatch positive-no EVT’’ group, and in the
‘‘mismatch positive-EVT’’ vs. ‘‘mismatch negative-
EVT’’ groups. As secondary outcomes, we chose the
improvement of the NIHSS at 24 h from the baseline
(delta NIHSS), and the rate of symptomatic intracer-
ebral hemorrhage (sICH) defined according to the
ECASS II criteria.14
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Statistics
We first analyzed demographic, clinical, and radio-
logical variables from the acute phase of stroke, per-
forming comparisons between the four study groups
defined by the presence of clinical-ASPECTS mismatch
(mismatch positive, mismatch negative) and acute treat-
ment modality (late EVT, no EVT). Baseline character-
istics of the cohort were summarized both overall and
separately for each group of patients, reporting fre-
quencies and percentages for binary and categorical
variables, and medians (and inter-quartile ranges,
IQR) for continuous measures. Comparisons were con-
ducted using appropriate statistical testing, i.e. Mann–
Whitney U for continuous variables and Chi-squared
or Fisher Exact test for categorical variables.
The primary outcome was analyzed using both uni-
variate and multivariable methods. We fitted ordered
logit regression models, including interaction terms
between the variables ‘‘clinical-ASPECTS mismatch’’
and ‘‘late EVT’’, with the response variable being the
shift towards favorable outcome (i.e. lower mRS) at
three months. A likelihood ratio test was used to
assess the assumption of proportional odds: no evi-
dence of non-proportional odds has emerged across
all the categories of mRS for each covariate in the
model (p> 0.05 for all).
We obtained four different odds ratios (ORs) com-
paring the four different groups of patients, and the OR
for the interaction term. First, unadjusted ORs were
calculated, and then a multivariable analysis was per-
formed, in which a list of variables was used to adjust
the ORs of interest. These included variables that had
been shown to influence outcome or because their
unbalanced distribution among the four groups. The
final, adjusted, model included the followings: age,
pre-stroke mRS< 3, LPGH to hospital arrival time,
admission NIHSS, admission glucose level, baseline
ASPECTS, and IVT.
Also, a sensitivity analysis was performed in the sub-
group of patients who had the CT as initial imaging
modality.
Secondary outcomes were analyzed using compara-
tive univariate logistic or linear regression models
(depending on the nature of the outcome variable).
Adjusted analyses were not performed for secondary
outcomes.
Given the retrospective registry-based analysis of
data, a formal sample size calculation was not per-
formed. However, a post hoc sample size assessment
was conducted: assuming an absolute benefit between
patients receiving late EVT and non-treated patients
being half of the one reported in the DAWN trial (i.e.
18%), we calculated that a sample size of 115 patients
would be required in each group, considering 80%
power and 5% alpha.
We performed complete case analyses, with only
observations with complete information being con-
sidered; hence, no formal treatment of missing data
was done.
Statistical analyses were performed using STATA
version 15 and R version 4.0.
This study was approved by the hospital’s
Institutional Review Board of each center for retro-
spective data collection and review.
Data accessibility statement
Anonymized data will be shared by request from any
qualified investigator.
Results
Out of 2242 AIS patients who received EVT during the
study period (2010–2018) in the two participating
stroke centers, 482 (21.5%) were treated between 6
and 24 h from LPGH. Of these, 218 (9.7%) patients
presented with admission NIHSS 10 and ICA/M1
occlusion, and were therefore included in the EVT-
arm. To select the no-EVT arm, we screened 1675
AIS patients admitted in the late time window to
Lausanne stroke center between 2005 and 2018, and
we identified 119 (7.1%) patients who did not receive
EVT and presented the clinico-radiological inclusion
criteria. The flow chart for the selection of the study
population is available in Figure 1S.
Therefore, the overall study cohort consisted of
337 AIS, with 172 patients from Lausanne and 165
patients from Bern stroke center. Their baseline
demographics, clinic and radiological features are
presented in Table 1. The median age was 73
(IQR¼ 61–82), with 52% females. The median
NIHSS on admission was 18 (15–22) and median
LPGH to hospital arrival was 9.2 (5.9–12.9) h. The
median ASPECTS was 7 (5–9) and 24% of patients
presented tandem occlusions.
One hundred ninety-six (58.2%) patients presented a
clinical-ASPECTS mismatch, of whom 146 (74.5%)
received EVT. Among 141 (41.8%) patients without
clinical-ASPECTS mismatch, EVT was performed in
72 (51.1%) patients.
The four groups of patients were well balanced for
demographics, stroke severity, and vascular risk fac-
tors, with the exception of diabetes (higher in the mis-
match positive – no EVT group) (Table 1). Patients
who did not receive EVT showed a lower proportion
of pre-stroke independency, longer delay from LPGH
to hospital arrival, and higher frequency of wake-up
strokes. Regarding neuroimaging features, more EVT
patients were assessed by MRI. The median ASPECTS
were lower in mismatch negative than in mismatch
International Journal of Stroke, 0(0)
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positive patients. Patients who did not receive EVT
were also treated less frequently with IVT.
EVT-patients with the clinical-ASPECTS mismatch
presented shorter delay between the groin puncture and
the recanalization when compared to patients without.
However, the median number of passes used and the
rate of successful recanalization (i.e. mTICI 2b) were
similar between the two groups.
The unadjusted ordinal shift analysis for three-
month mRS showed that late EVT was associated
with better outcome than absence of treatment in
both patients with the clinical-ASPECTS mismatch
(OR¼ 2.27; 95%CI¼ 1.21–4.16) and patients without
the clinical-ASPECTS mismatch (OR¼ 2.34; 95%
CI¼ 1.26–4.42). Also, among patients treated with
late EVT, patients showing the clinical-ASPECTS mis-
match presented better outcome compared to those
without (OR¼ 1.74; 95%CI¼ 1.06–2.90) (Table 2).
After adjusting for confounders, a favorable effect of
late EVT on clinical outcome emerged in the mismatch
positive group (OR¼ 2.83; 95%CI¼ 1.48–5.58), but no
more in the mismatch negative group (OR¼ 1.32;
95%CI¼ 0.61–2.84). In this model, moreover, we
found a near significant positive interaction between
the clinical-ASPECTS mismatch and late EVT
(p¼ 0.073) (Table 2).
Sensitivity analysis evaluating the primary outcome
in the subgroup of patients assessed initially with CT
only (N¼ 241) confirmed the direction and the magni-
tude of the ORs seen in the primary analysis, although
the differences were no longer statistically significant
(see Table 1S in the Supplementary material).
At 24 h, mismatch positive patients treated with late
EVT showed a greater improvement in the NIHSS
score compared to non-treated patients and mismatch
negative patients (p< 0.001, Table 3). Compared to
non-treated patients, patients receiving EVT showed
higher rate of sICH (5% in mismatch positive patients,
13% in mismatch negative patients) (p¼ 0.017). At
three months, only 25% of all patients achieved func-
tional independency; this rate was significantly lower in
non-treated patients without clinical-ASPECTS mis-
match (7%, p< 0.001) (Figure 1). Also, there was a
significant disproportion of mortality rates between
the four groups (p¼ 0.002), with non-treated patients
presenting higher proportions (42% in mismatch posi-
tive patients, 49% in mismatch negative patients)
(Table 3 and Figure 1).
Table 2. Results from the shift analyses for favorable outcome at three months (assessed with modified Rankin Scale) according to
presence of clinical-ASPECTS mismatch and late endovascular treatment.
Patients group OR 95%CI p-value
Unadjusted comparison
EVT vs. No EVT Mismatchþ 2.27 1.21–4.16 0.007*
Mismatch 2.34 1.26–4.42 0.008*
Mismatchþ vs. Mismatch EVT 1.74 1.06–2.90 0.030*
No EVT 1.68 0.83–3.38 0.147
Interactiona 1.10 0.47–2.58 0.832
Adjusted comparisonb
EVT vs. No EVT Mismatchþ 2.83 1.48–5.58 0.002*
Mismatch 1.32 0.61–2.84 0.484
Mismatchþ vs. Mismatch EVT 0.82 0.36–1.84 0.624
No EVT 2.11 0.55–8.31 0.282
Interactiona 2.33 0.93–5.94 0.073
Note: Results are shown as odds ratios (OR) and their 95% confidence interval (CI), both for unadjusted and adjusted comparison.
*and bold characters means significant results.
aRefers to the interaction term between the presence of clinical-ASPECTS mismatch and late-EVT performed.
bAdjusted for: age, pre-stroke mRS, LPGH to presentation, NIHSS on admission, glucose on admission, baseline ASPECTS, IV thrombolysis.
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Discussion
In our large, retrospective analysis of a two-centers
cohort of late-arriving stroke patients undergoing
EVT in routine clinical practice, we demonstrated a
clinical benefit of the revascularization procedure in
patients showing a mismatch between the stroke sever-
ity (assessed by NIHSS) and the amount of
irreversibly damaged cerebral tissue (evaluated with
the ASPECTS). After adjustment for multiple con-
founders, we found a near significant positive inter-
action between the treatment effect in the late time
window and the selection of patients according to
the proposed clinical-ASPECTS mismatch. In thus
selected patients, treatment was also associated with
early neurological improvement, similar risk of
Figure 1. Distribution of scores for disability on the modified Rankin Scale (mRS) at 90 days among late-arriving patients who
received (EVT) and did not receive endovascular treatment (No EVT), both in the subgroup of patients showing the clinical-
ASPECTS mismatch (Mismatchþ, top two bars) and in subgroup of patients without the clinical-ASPECTS mismatch (Mismatch,
bottom two bars). The scale ranges from 0 to 6, with higher scores indicating more severe disability. The numbers in the bars are
percentages of patients who had each score.
















Delta NIHSS at 24 h, median (IQR) 1 (7; 0) 6 (10; 0) 1 (2; 0) 0 (6; 2) 0 (1;1) <0.001*
sICH, n (%) 18 (6) 7 (5) 2 (4) 9 (13) 0 (0) 0.017*
3-month mRS¼ 0–2, n (%) 85 (25) 53 (36) 11(22) 16 (22) 5 (7) <0.001*
3-month mRS, median (IQR) 4 (2; 6) 4 (2; 6) 5 (3; 6) 4 (3; 6) 5 (4; 6) 0.001*
Death <3 months, n (%) 115 (34) 35 (24) 21 (42) 25 (35) 34 (49) 0.002*
NIHSS: National Institutes of Health Stroke Scale; delta NIHSS: NIHSS at 24 h – NIHSS on admission; mRS: modified Rankin Scale; mismatch: clinical-
ASPECTS mismatch; EVT: endovascular treatment.
Note: UVA results from the comparison between groups are provided.
*and bold characters mean significant results.
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symptomatic hemorrhagic transformation, and lower
mortality rate compared to non treated patients.
Real-world data regarding prevalence, treatments,
and outcomes of LVO patients admitted in the
extended time window fulfilling and not fulfilling
DAWN and/or DEFUSE-3 criteria are very lim-
ited.15,16 These reports suggest that a less restrictive
cut-off on infarct core volume was still able to select
patients responding to late EVT. However, a simpler
neuroimaging protocol for patients’ selection for mech-
anical thrombectomy beyond 6 h has not been tested
yet, except in small case series.8,17 Our retrospective
data show that a clinical-ASPECTS mismatch concept
has potential value and safety to select patients for late
thrombectomy, and that it might be not necessary to
use more sophisticated perfusion imaging for this
population.
Previous reports showed a moderate correlation
between ASPECTS and core volumes on CTP.18,19 We
previously demonstrated that ASPECTS assessment on
NCCT seemed to be more accurate in later time win-
dows and in patients with LVO, supporting the findings
of our current analysis.12 This group of late-arriving
patients might include patients with unknown onset or
wake-up stroke, when the ASPECTS may be less reli-
able if the patient is actually early on after onset. Still,
we did not find a significant difference in the strength of
the ASPECTS-CTP-core correlation between patients
with known and unknown stroke onset.12
Rates of good outcomes in our EVT cohort (36% in
the mismatch positive patients and 22% in the mis-
match negative patients) were lower compared to
those found in the HERMES meta-analysis for
EVT< 6 h,20 and in the DAWN (49%) and
DEFUSE-3 (45%) trials. This could be explained by
the real-life scenario of our study, including 20% of
patients with significant pre-stroke disability
(mRS 3). The non-treated group of our study also
showed a rather poor natural course (with 16% patients
achieving a good outcome), which was similar to the
rates of functional independence in the control arm of
DAWN (13%) and DEFUSE-3 (17%).
We found acceptable safety measures in our cohort
of late EVT patient using less sophisticated imaging
criteria: late EVT was not associated with higher risk
of sICH in patients showing a clinical-ASPECTS mis-
match (5% in treated patients vs. 4% in non-treated
patients), with similar rates to those reported in late
EVT trials. However, we found an increased risk of
sICH for patients treated with late EVT not having
the clinical-ASPECTS mismatch (13%). The median
ASPECTS of these patients was low;5 therefore, this
result is in line with the higher risk of intracranial hem-
orrhage after early EVT shown for patients with
ASPECTS 0-4.21
Similarly, we found an increased mortality risk in
treated patients not having the clinical-ASPECTS mis-
match compared to treated patients showing the mis-
match (35% vs. 24%, respectively); however, the EVT
treatment was overall associated with a lower mortality
risk when compared to non-treated patients (with 42%
of deaths in the non-treated mismatch positive and
49% in the non-treated mismatch negative group,
respectively). These percentages are in line with those
observed in the DAWN trial (i.e. 25% in the thromb-
ectomy group vs. 36% in the control group).
We acknowledge several limitations of our study.
First, the nonrandomized and retrospective nature of
the study might limit the generalization of the results.
Second, it is possible that variables related to the deci-
sion to perform endovascular treatment have influenced
our results; we have attempted to reduce this potential
bias by including several of these variables in the adjust-
ment for our final model. Third, the number of patients
in each subgroup was likely insufficient to prove our
hypotheses, leading to type II errors: our post hoc
power calculation showed that more patients would be
needed to prove the expected 18% improvement in the
clinical outcome with 80% power. Therefore, the not
quite significant p-value for interaction, as well as the
absence of significance in the sensitivity analysis of CT-
selected patients, might be explained by the low number
of included patients. Fourth, the difference of neuroima-
ging modalities adopted in each center (with DWI-
based ASPECTS mostly adopted in the EVT-group,
and NCCT-based ASPECTS used for the non-treated
group) might have influenced our results. Fifth, due to
the long study period, especially for the non-treated
arm, the outcomes measures might have been influenced
by the improvement of revascularization treatments and
general stroke care over time. Similarly, the differences
in treatment selection approach between the two parti-
cipating centers and over the study period might be a
source of bias. Last, our goal was to assess the impact of
patient selection for EVT on the real-world scenario of
absent perfusion imaging where core volume cannot be
precisely measured; therefore, perfusion-based analyses
were not included in the current project.
Conclusions
In our real-world analysis of consecutive stroke
patients with proximal anterior circulation LVO,
there seemed to be a more favorable outcome with
late endovascular treatment in the setting of a mis-
match between clinical severity and ASPECTS. This
result could suggest a potential role of simpler neuroi-
maging protocols in late revascularization decisions,
but confirmation by randomized controlled studies is
needed.
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